Gemcitabine in ovarian cancer: An overview of safety and efficacy
- 31 January 1997
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 33, S31-S33
- https://doi.org/10.1016/s0959-8049(96)00338-3
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Safety profile of gemcitabineAnti-Cancer Drugs, 1995
- Phase II Study of Gemcitabine (2',2'-Difluorodeoxycytidine) in Previously Treated Ovarian Cancer PatientsJNCI Journal of the National Cancer Institute, 1994
- Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.Journal of Clinical Oncology, 1994
- Choice of postoperative therapy based on prognostic factorsInternational Journal of Radiation Oncology*Biology*Physics, 1982